Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06836063 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate Efficacy and Safety of Ropanicant in MDD Patients
A Phase 2 study of Major Depressive Disorder (MDD), sponsored by Suven Life Sciences Limited.
- Active
- Registry status
- Phase 2
- Development phase
- 195
- Enrollment target
- 20
- Study locations
NCT06836063: Active Phase 2 study of Major Depressive Disorder (MDD), sponsored by Suven Life Sciences Limited.
NCT06836063 is a Phase 2 study of Major Depressive Disorder (MDD) that is active but no longer recruiting, run by Suven Life Sciences Limited. The registered enrollment target is 195 participants, above the 150-participant average among 22 other Major Depressive Disorder (MDD) trials with a reported enrollment target (30% higher). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06836063, a Phase 2 study of Major Depressive Disorder (MDD), is active but no longer recruiting, sponsored by Suven Life Sciences Limited.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 195 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective is to evaluate the efficacy of Ropanicant at two different dosage levels compared to placebo in patients with Major Depressive Disorder (MDD).
Primary Outcome
The MADRS is a clinician-rated scale to assess depressive symptoms which consists from 10 items. The time frame for this scale is the past 7 days. Each item is scored on 7-point scale (0 \[absence of symptoms\] to 6 \[severe\]). The total score is the sum of 10 items and can take range from 0 to 60. A higher score represents a higher severity of the level of depression.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Ropanicant
Study Locations (20)
California
- Advanced Research Center, Inc. - Anaheim
- ProScience Research Group - Culver City
- Behavioral Research Specialists, LLC - Glendale
- Synergy San Diego - Lemon Grove
- Excell Research, Inc. - Oceanside
- ATP Clinical Research - Orange
- Collaborative Neuroscience Research - Torrance
Florida
- Clinical Neuroscience Solutions, Inc. - Jacksonville
- Premier Clinical Research Institute, Inc - Miami
- Clinical Neuroscience Solutions, Inc. - Orlando
- Panhandle Research and Medical Clinic LLC - Pensacola
- ForCare Clinical Research - Tampa
Georgia
- Atlanta Center for Medical Research - Atlanta
- CenExcel iResearch LLC - Decatur
- CenExcel iResearch LLC - Savannah
Arkansas
- Woodland International Research Group LLC - Little Rock
- Woodland Research Northwest - Rogers
Illinois
- Chicago Research Center Inc. - Chicago
Michigan
- Neurobehavioral Medicine Group - Bloomfield Hills
Mississippi
- Precise Research Centers - Flowood
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 195 participants |
| Start Date | 2025-07-15 |
| Est. Completion | 2026-02-28 |
| Phase | Phase 2 |
What the registry record for NCT06836063 still lists
NCT06836063 is an interventional study that assigns participants to a tested intervention. The registered 195 participants enrollment target is mid-sized for trials with a published cap, above the 150-participant average among 22 other Major Depressive Disorder (MDD) trials with a reported enrollment target (30% higher).
The record links to 1 condition, with Major Depressive Disorder (MDD) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06836063 names 20 study sites across 7 states, led by California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT06836063 about?
NCT06836063 is a clinical study titled "Study to Evaluate Efficacy and Safety of Ropanicant in MDD Patients". The primary objective is to evaluate the efficacy of Ropanicant at two different dosage levels compared to placebo in patients with Major Depressive Disorder (MDD).
What is the current status of trial NCT06836063?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 195 participants. The study started on 2025-07-15. Estimated completion is 2026-02-28.
What conditions does trial NCT06836063 study?
This clinical trial studies the following conditions: Major Depressive Disorder (MDD).
What interventions are being tested in trial NCT06836063?
The interventions under investigation include: Placebo (DRUG), Ropanicant (DRUG).
Who is sponsoring clinical trial NCT06836063?
This trial is sponsored by Suven Life Sciences Limited, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06836063 being conducted?
This trial has 20 study locations across Arkansas, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Major Depressive Disorder (MDD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06836063's enrollment target sits among peer trials
195 9th of 22 higher than 14 of 22 other Major Depressive Disorder (MDD) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Major Depressive Disorder (MDD) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response
RECRUITING · Phase 2
-
A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression
RECRUITING · Phase 2
-
Orexin Antagonism for Suicide Risk: A Proof-of-Concept Clinical Trial
RECRUITING · Phase 2
-
A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)
RECRUITING · Phase 2
-
A Study in Patients With Major Depressive Disorder
ACTIVE NOT RECRUITING · Phase 2
-
Improving Depression Outcome by Enhancing Memory for Cognitive Therapy
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04276922 · 195 participants · NA
Creative Arts Program to Reduce Burnout in Healthcare Professionals
- NCT04829357 · 195 participants
Post Market Clinical Follow-up Study on TVT ABBREVO® Continence System
- NCT05054738 · 195 participants · NA
CRP and S&A for Inpatient Veterans
- NCT05561595 · 195 participants · NA
Transdiagnostic Intervention to Reduce Internalized Health-Related Stigma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI